DUKE UNIVERSITY
Total received in grants · trailing 12 months
$90M
$1for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $401.9B in tracked grants
10separate grants, trailing 12 months
DUKE UNIVERSITY has received $90M across 10 federal grants of $1M or more on record.
Data as of August 5, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Energy | STUDIES OF NUCLEAR STRUCTURE USING NEUTRONS AND CHARGED PARTICLES | $66,285,317 |
| Department of Energy | VIA MULTI-SECTOR, TRANSDISCIPLINARY COLLABORATION, AND IN CONSULTATION WITH WIND ENERGY STAKEHOLDERS, WE WILL DEVELOP A STRUCTURED FRAMEWORK FOR COMPREHENSIVE EVALUATION OF POTENTIAL EFFECTS OF OFFSHORE WIND ENERGY ON WILDLIFE AND HABITATS, ACROSS A RANGE OF SPATIAL AND TEMPORAL SCALES. THE PROJECT GOALS ARE FRAMED AROUND DEFINED MANAGEMENT AND CONSERVATION QUESTIONS AND AIM TO IMPROVE OUR UNDERSTANDING OF THE EFFECTS OF OFFSHORE WIND ENERGY DEVELOPMENT ON WILDLIFE AND HABITATS, POSITIVE OR NEGATIVE; TO IMPROVE OUR UNDERSTANDING OF THE MECHANISMS FOR THESE EFFECTS; TO DISTINGUISH BETWEEN SHORT-AND LONG-TERM EFFECTS, AS WELL AS THEIR CUMULATIVE OR POPULATION-LEVEL RAMIFICATIONS; AND TO FURTHER DEVELOP AND VALIDATE METHODS FOR EXAMINING AND ASSESSING THESE EFFECTS. WE WILL DO THIS THROUGH STRATEGIC MONITORING AND INTEGRATED RESEARCH, SYNCHRONIZED WITH PLANNED DEVELOPMENT ACTIVITIES, THAT WILL ENABLE STATE AND FEDERAL AGENCIES AND WIND ENERGY DEVELOPERS TO INTEGRATE LOCAL-SCALE INFORMATION WITH EXISTING REGIONAL AND ECOSYSTEM-LEVEL SCIENTIFIC DATA TO INTER ALIA REDUCE UNCERTAINTY IN IMPACT ASSESSMENTS AT BOTH THE INDIVIDUAL AND POPULATION LEVELS. | $7,437,346 |
| Department of Health and Human Services | THE ROLE OF TRP ION CHANNELS IN MIGRAINE PAIN - ABSTRACT MIGRAINE IS A HIGHLY PREVALENT AND COMPLEX NEUROLOGICAL DISORDER THAT DISPROPORTIONATELY AFFECTS WOMEN AND POSES A SIGNIFICANT ECONOMIC BURDEN, WITH ANNUAL TREATMENT COSTS EXCEEDING $20 BILLION IN THE UNITED STATES ALONE. DESPITE ITS IMPACT, THE PRECISE MECHANISMS UNDERLYING MIGRAINE PATHOPHYSIOLOGY REMAIN INCOMPLETELY UNDERSTOOD. OUR LONG-TERM GOAL IS TO DEFINE THE MECHANISMS THAT UNDERLIE MIGRAINE PAIN, AND TO PROVIDE NOVEL AND EFFECTIVE APPROACHES TO REDUCE ITS OCCURRENCE. EMERGING CANDIDATES IN MIGRAINE RESEARCH ARE THE TRANSIENT RECEPTOR POTENTIAL VANILLOID (TRPV) CALCIUM ION CHANNELS, AMONG WHICH TRPV4 IS A MEMBER. TRPV4 IS EXPRESSED IN KEY COMPONENTS OF THE TRIGEMINAL SENSORY SYSTEM, INCLUDING TRIGEMINAL (TG) SENSORY NEURONS, MENINGEAL MAST CELLS (MCS), AND SATELLITE GLIAL CELLS (SGCS). TRPV4 PLAYS CRITICAL ROLES IN PAIN PERCEPTION AND NEUROINFLAMMATION, MAKING IT A PROMISING TARGET FOR INVESTIGATING MIGRAINE PATHOPHYSIOLOGY. HOWEVER, THE SPECIFIC ROLE OF TRPV4 IN THE TRIGEMINAL SENSORY SYSTEM IN THE CONTEXT OF MIGRAINES REMAINS A GAP IN KNOWLEDGE. MCS AND SGCS INFLUENCE PAIN SENSITIVITY AND TG NEURONAL EXCITABILITY, MAKING THEM PRIME CANDIDATES FOR EXPLORING MIGRAINE PATHOPHYSIOLOGY. TRPV4 INVOLVEMENT IN PAIN AND MIGRAINE, ALONG WITH ITS EXPRESSION IN BOTH MCS AND SGCS, FURTHER SUPPORTS ITS ROLE IN MIGRAINE-RELATED PROCESSES. THE CENTRAL HYPOTHESIS OF THIS PROPOSAL IS THAT TRPV4 CA2+-PERMEABLE ION CHANNELS IN MCS AND SGCS CONTRIBUTE TO MIGRAINE PAIN AND DO SO IN A SEX SPECIFIC MANNER. TO TEST THIS HYPOTHESIS, WE AIM TO INVESTIGATE THE TRPV4 IN MENINGEAL MCS AS IT IMPACTS MIGRAINE-RELATED PAIN AND EXAMINE THE SENSITIZING IMPACT OF TRPV4 IN SGCS ON TRIGEMINAL SENSORY NEURONS. FEASIBILITY FOR THESE MODELS AND TECHNIQUES HAS BEEN ESTABLISHED BY THE APPLICANTS AND COLLABORATORS. OUR INNOVATIVE APPROACH, WHICH INCLUDES TG NEURON-MC CO-CULTURE TECHNIQUES, MC AND SGC-SPECIFIC TRPV4 DELETION IN MICE, IN-VIVO MIGRAINE PAIN BEHAVIORAL ASSESSMENTS, IN-VIVO LIVE ANIMAL MONITORING POST-MIGRAINE INDUCTION, AND AAV GLIA-TARGETED TRPV4 KNOCKDOWN AIMS TO ELUCIDATE THE MECHANISMS BY WHICH TPRV4 IN THESE CELL LINEAGE CANDIDATES DRIVE MIGRAINE AND TO EVALUATE THE TRANSLATIONAL RELEVANCE TO HUMAN MIGRAINE PATHOLOGY. THE RATIONALE OF THIS RESEARCH IS THAT ITS SUCCESSFUL COMPLETION WILL ADVANCE OUR UNDERSTANDING OF HOW TRPV4-MEDIATED SIGNALING INFLUENCES THE MECHANISMS UNDERLYING MIGRAINE PATHOPHYSIOLOGY, OFFERING PROMISING AVENUES FOR THE DEVELOPMENT OF TARGETED THERAPEUTIC INTERVENTIONS TO ALLEVIATE THE MIGRAINE BURDEN AND ENHANCE PATIENT OUTCOMES WORLDWIDE. | $3,833,890 |
| Department of Health and Human Services | DOES SWITCHING TO PAID FAMILY CARE (VERSUS PAID AIDES) INCREASE TIME AT HOME OR REDUCE PUBLICLY FUNDED HEALTHCARE COSTS FOR MEDICAID WAIVER BENEFICIARIES WITH DISABILITY? - REVISED THERE IS A LONG HISTORY OF STATE’S HEALTH AND HUMAN SERVICES DEPARTMENTS OBTAINING WAIVERS TO OFFER SELF-DIRECTED CARE FOR MEDICAID BENEFICIARIES WITH INTENSIVE HOME CARE NEEDS. MANY STATES PROVIDE FLEXIBILITY IN HOW WAIVER BENEFICIARIES CAN EXERCISE SELF-DIRECTION, INCLUDING CHOOSING AN AGENCY-PROVIDED AIDE OR A QUALIFYING ELIGIBLE FAMILY MEMBER. ABILITY TO PAY A FAMILY MEMBER ACCELERATED IN 2020, WHEN SCARCITY OF AIDES DROVE STATES TO ALLOW SWITCHING FROM AN AIDE TO A FAMILY MEMBER; SCANT EVIDENCE ON THE EFFECTS ON PERSON-CENTERED OUTCOMES EXISTS TO SUPPORT DISSOLUTION OR EXPANSION. IN FACT, AVAILABLE EVIDENCE FROM A CLINICAL DEMONSTRATION SUGGESTS PAYMENT-INDUCED FAMILY CARE CAUSALLY REDUCES PATIENT ACUTE CARE USE, INPATIENT EXPENDITURES, AND ADVERSE OUTCOMES. WHAT REMAINS UNKNOWN, HOWEVER, IS WHETHER PAID FAMILY CARE INCREASES BENEFICIARIES’ ABILITY TO REMAIN SAFELY AT HOME OR CHANGES PUBLICLY FUNDED HEALTHCARE COSTS IN REAL WORLD MEDICAID PROGRAMS. WITH NO NATIONAL DATA ON “WHO IS PAID”, THIS STUDY AIMS TO ADDRESS THESE KNOWLEDGE GAPS USING NORTH CAROLINA (NC) AS A CASE TO EXAMINE AN UNDERSTUDIED WAIVER BENEFICIARY POPULATION: ADULT PATIENTS LIVING WITH DISABILITY. THIS BENEFIT DESIGN CHANGE WAS PLAUSIBLY EXTERNAL TO INDIVIDUAL HEALTH STATUS, SINCE SWITCHING AROSE FROM NECESSITY AS AIDES BECAME SCARCE. AND YET, PREFERENCES ALSO COULD DRIVE A SWITCH, MAKING THE CHOICE OF PROVIDER TYPE NOT RANDOM. THEREFORE, THE OBJECTIVES OF THE CURRENT FIVE-YEAR R01 STUDY ARE TO USE CAUSAL METHODS TO COMPARE THE EFFECT OF SWITCHING TO FAMILY CARE ON PERSON-CENTERED OUTCOMES, POTENTIAL HARMS AND PUBLIC EXPENDITURES FOR ADULT NC MEDICAID WAIVER BENEFICIARIES LIVING WITH DISABILITY. WE WILL DESCRIPTIVELY EVALUATE NC’S BENEFIT DESIGN CHANGE LINKING CLAIMS, MANAGED CARE, AND PROGRAM DATA FROM 2017-2025 (AIM 1), COMPARING A) BENEFICIARIES WHO SWITCHED FROM AIDES TO PAID FAMILY CARE AND B) BENEFICIARIES WHO REMAINED WITH AIDES, FOCUSING ON THE FULL SAMPLE AND THOSE WITH SPECIFIC INDIVIDUAL (E.G., AGE), GEOGRAPHIC (E.G., RURALITY), AND DIAGNOSTIC CHARACTERISTICS (E.G., DEMENTIA). USING RIGOROUS QUASI-EXPERIMENTAL METHODS, WE WILL ESTIMATE THE AVERAGE TREATMENT EFFECT OF SWITCHING FROM PAID AIDE CARE EXCLUSIVELY TO PAID FAMILY CARE ON PERSON-CENTERED OUTCOMES, POTENTIAL HARMS (AIM 2) AND PUBLIC EXPENDITURES (AIM 3) 6-48 MONTHS POST-SWITCH COMPARED TO A NON-EQUIVALENT COMPARISON GROUP OF NON-SWITCHERS. PERSON-CENTERED OUTCOMES WERE SELECTED TO REFLECT BENEFICIARY PREFERENCE TO REMAIN WELL AT HOME: (A) PREVENTIVE OUTPATIENT CARE, (B) [PRIMARY] CUMULATIVE DAYS AT HOME, OR DAYS NOT SPENT IN EMERGENCY, INPATIENT, OR POST-ACUTE CARE SETTINGS (OR “HOME TIME”), (C) AVOIDED TREAT AND RELEASE EMERGENCY DEPARTMENT VISITS, AND (D) DELAYED PERMANENT NURSING HOME TRANSITIONS. POTENTIAL HARMS WERE SELECTED TO CAPTURE OUTCOMES TO BE AVOIDED: (E) POTENTIALLY INAPPROPRIATE MEDICATIONS, (F) FALL-RELATED INJURIES, AND (G) MISTREATMENT. WE WILL EXPLORE EFFECTS ON PRE-SPECIFIED SUBGROUPS OF SWITCHING TO PAID FAMILY CARE (VS. NOT SWITCHING) ON PCOS AND HARMS 6-48 MONTHS POST-SWITCH BY INDIVIDUAL, GEOGRAPHIC, AND DIAGNOSTIC CRITERIA (AIM 4). EXAMINING THIS CHANGE IN SELF-DIRECTION, WHICH DRIVES A PLAUSIBLY CAUSAL SHIFT IN THE SUPPLY OF “WHO IS PAID” TO PROVIDE HOME CARE (FAMILY VERSUS AIDES ALONE), ALIGNS WITH NIA’S 2020-2025 STRATEGIC GOAL TO IMPROVE THE HEALTH, WELL-BEING, AND INDEPENDENCE OF ADULTS AS THEY AGE. RESULTS WILL BE IMMEDIATELY ACTIONABLE BY INFORMING HEALTHCARE PROVIDERS, HEALTH SYSTEMS, HOSPITALS, AND PATIENTS ABOUT HOW THE TYPE OF HOME CARE PROVIDER DIRECTLY AFFECTS THE HEALTH AND HEALTHCARE OF PATIENTS LIVING WITH DISABILITY. | $3,272,015 |
| Department of Defense | ELUCIDATING AND MITIGATING THE EFFECTS OF DAMAGE-ASSOCIATED MOLECULAR PATTERNS (DAMPS) RELEASED FOLLOWING SEVERE TRAUMATIC INJURY | $1,996,095 |
| Department of Energy | DEVELOPMENT OF HIGH VALUE BIOPRODUCTS AND ENHANCEMENT OF DIRECT-AIR CAPTURE EFFICIENCY WITH A MARINE ALGAE BIOFUEL PRODUCTION SYSTEM | $1,967,473 |
| Department of Health and Human Services | 2/2 CATHETER ABLATION VERSUS ANTIARRHYTHMIC AND HEART FAILURE DRUG THERAPY IN PRESERVED EJECTION FRACTION HEART FAILURE (CABANA-HF) - ATRIAL FIBRILLATION (AF) OFTEN COEXISTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), AND WHEN PRESENT IN COMBINATION PORTENDS A WORSE PROGNOSIS. HFPEF AND AF ARE CLOSELY RELATED AS THEY SHARE LEFT ATRIAL (LA) DYSFUNCTION AS A COMMON PATHOPHYSIOLOGIC RISK FACTOR. FURTHERMORE, AF IS A RISK FACTOR FOR HFPEF; AND HFPEF IS A RISK FACTOR FOR AF. THE PRESENCE OF AF IN HFPEF IS ALSO A MARKER OF LA MYOPATHY, WHICH CONTRIBUTES TO PULMONARY VENOUS CONGESTION, PULMONARY VASCULAR DISEASE, RIGHT HEART FAILURE, CARDIORENAL SYNDROME, HF HOSPITALIZATION, AND DEATH. PATIENTS WITH HFPEF AND LA MYOPATHY ALSO CANNOT APPROPRIATELY AUGMENT STROKE VOLUME DURING EXERTION, RESULTING IN DEPENDENCE ON INCREASES IN HEART RATE TO AUGMENT CARDIAC OUTPUT. THUS, A RATE CONTROL STRATEGY FOR AF IN HFPEF MAY BE DETRIMENTAL AND CAN LEAD TO WORSE SYMPTOMS AND EXERCISE TOLERANCE. DESPITE ALL THAT IS KNOWN ABOUT COMORBID HFPEF AND AF, OPTIMAL TREATMENT OF AF, INCLUDING IDEAL INDICATIONS AND TIMING OF ABLATION OF AF, IN HFPEF REMAINS UNCLEAR. THERE ARE APPROXIMATELY 1.2 MILLION PATIENTS WITH HFPEF AND AF IN THE US. OVER THE NEXT DECADE, THE PREVALENCE OF HFPEF WITH AF IS PROJECTED TO INCREASE BY AROUND 50% DUE TO THE AGING OF THE POPULATION AND THE INCREASING PREVALENCE OF KEY RISK FACTORS. CURRENTLY, LESS THAN 5% OF PATIENTS WITH HFPEF AND AF RECEIVE CATHETER ABLATION FOR ATRIAL FIBRILLATION, MOSTLY FOR SYMPTOM CONTROL. AN APPROPRIATELY POWERED AND RIGOROUS RANDOMIZED CLINICAL TRIAL OF AF ABLATION IN HFPEF IS THEREFORE A CRITICAL UNMET NEED. WE PROPOSE THE CATHETER ABLATION VERSUS ANTIARRHYTHMIC AND HEART FAILURE DRUG THERAPY IN PRESERVED EJECTION FRACTION HEART FAILURE (CABANA-HF) TRIAL, A 1552-PATIENT MULTI-CENTER, RANDOMIZED, TWO-ARM, OPEN LABEL TRIAL DESIGNED TO TEST WHETHER CATHETER ABLATION FOR AF IN HFPEF ADDED TO GUIDELINE- DIRECTED MEDICAL THERAPY (GDMT) IMPROVES PROGNOSIS RELATIVE TO GDMT ALONE. THE CABANA-HF RESEARCH PROPOSAL CONSISTS OF TWO LINKED GRANT APPLICATIONS: THE CLINICAL COORDINATING CENTER (CCC) AND THE DATA COORDINATING CENTER (DCC). THIS APPLICATION IS FOR THE DCC. THE PRIMARY AIM OF THE TRIAL WILL BE TO DETERMINE WHETHER ROUTINE PERCUTANEOUS LEFT ATRIAL CATHETER ABLATION IS SUPERIOR TO OPTIMAL GUIDELINE-DIRECTED MEDICAL THERAPY (GDMT) ALONE. THE PRIMARY ENDPOINT WILL BE THE COMPOSITE OF CARDIOVASCULAR (CV) MORTALITY OR A WORSENING HF EVENT. A BLINDED (TO TREATMENT ASSIGNMENT) INDEPENDENT CLINICAL EVENTS COMMITTEE WILL REVIEW AND CLASSIFY ALL PRIMARY AND MAJOR CLINICAL SECONDARY EVENTS. MAJOR SECONDARY ENDPOINTS OF THE TRIAL WILL INCLUDE ALL-CAUSE MORTALITY, ALL-CAUSE MORTALITY OR WORSENING HF EVENTS, TIME TO RECURRENT AF, QUALITY OF LIFE, AND INCREMENTAL COST EFFECTIVENESS. THE CONCERN OF INCREASING MORBIDITY AND MORTALITY IN HFPEF PATIENTS WITH AF, ALONG WITH LIMITATIONS IN RESULTS OF PAST STUDIES AND PROMISING PRELIMINARY DATA, PROVIDES A SUFFICIENT INCENTIVE TO UNDERTAKE THIS TRIAL WITH AN ANTICIPATED HIGH LIKELIHOOD OF GUIDELINE-CHANGING RESULTS FROM THE CABANA-HF TRIAL. | $1,571,639 |
| Department of Defense | TARGETING NUAK2 IN NEUROENDOCRINE PROSTATE CANCER | $1,423,676 |
| Department of Defense | RAPID ANALOG PROCESSING FOR TACTICAL OBSERVATION AND OPPORTUNISTIC RADIO SPECTRUM ACCESS (RAPTORS) | $1,347,000 |
| Department of Health and Human Services | A MULTISCALE APPROACH TO DEFINING HIGH-RISK LESIONS AND NEIGHBORHOODS FOR BREAST PRECANCERS - TECHNICAL ABSTRACT DUCTAL CARCINOMA IN SITU (DCIS) IS ONE OF THE MOST COMMON HUMAN PRECANCERS, DIAGNOSED IN OVER 50,000 WOMEN IN THE US ANNUALLY. DESPITE THE HIGHLY VARIABLE RISK OF PROGRESSION TO INVASION, 98% OF DCIS IS CURRENTLY TREATED WITH SURGICAL EXCISION, OFTEN COMBINED WITH RADIATION, TO PREVENT INVASIVE CANCER. FOR THOSE PATIENTS WITH HIGH RISK OF PROGRESSION, AGGRESSIVE TREATMENT IS WARRANTED. HOWEVER, FOR DCIS AT LOW RISK OF PROGRESSION TO INVASIVE CANCER, THERE MAY BE LITTLE OR NO CLINICAL BENEFIT TO SURGERY. SINCE CURRENT GUIDELINES RECOMMEND THAT ALL PATIENTS WITH DCIS HAVE SURGERY, VIRTUALLY ALL PRIOR ANALYSES, INCLUDING OUR OWN, HAVE BEEN LIMITED TO PATIENTS WHO HAD SURGICAL EXCISION, WITH RECURRENCE OF DISEASE SERVING AS AN IMPERFECT PROXY FOR INVASIVE PROGRESSION. EPIDEMIOLOGIC EVIDENCE SUGGESTS THAT ONLY 20-30% OF DCIS PROGRESS. THUS, SOME PATIENTS MAY DERIVE LITTLE BENEFIT FROM SURGERY, AND THEREFORE COULD BE MANAGED WITH ACTIVE SURVEILLANCE (I.E. CLOSE MONITORING WITHOUT SURGERY), SIMILAR TO AN APPROACH NOW BROADLY ACCEPTED FOR EARLY-STAGE PROSTATE CANCER. HOWEVER, THERE ARE CURRENTLY NO PREDICTORS TO DETERMINE WHICH PATIENTS MAY SAFELY AVOID SURGERY. RECENTLY, FOUR INTERNATIONAL CLINICAL TRIALS HAVE BEEN LAUNCHED TO EVALUATE THE FEASIBILITY OF ACTIVE SURVEILLANCE FOR DCIS, AND BOTH DATA AND CLINICAL SAMPLES OF PATIENTS UNDERGOING ACTIVE SURVEILLANCE ARE NOW STARTING TO EMERGE. HERE, WE PROPOSE TO DETERMINE THE BIOLOGIC BEHAVIOR OF DCIS DURING THE COURSE OF ACTIVE SURVEILLANCE, WITH THE GOAL OF ELIMINATING THE NEED FOR SURGERY IN PATIENTS WITH THE LOWEST BIOLOGIC RISK FOR INVASIVE PROGRESSION. WE WILL INVESTIGATE ALTERATIONS IN BOTH DCIS TUMORS AND THEIR CELL NEIGHBORHOODS TO DEFINE THE MOLECULAR AND CELLULAR EVENTS CONFERRING THE HIGHEST RISK OF INVASION IN THE ABSENCE OF SURGICAL EXCISION. OUR AIMS ARE THE FOLLOWING: AIM 1: ASSESS THE MOLECULAR VARIATION OF DCIS WITH RESPECT TO THE BIOLOGIC PATHWAYS AND EVOLUTIONARY DYNAMICS THAT DISTINGUISH PROGRESSORS FROM NON-PROGRESSORS OVER TIME IN A UNIQUE COHORT OF PATIENTS WITH DCIS UNDERGOING ACTIVE SURVEILLANCE WITH REPEATED SAMPLING. AIM 2: IDENTIFY THE MOLECULAR FEATURES AT SINGLE CELL RESOLUTION THAT CHARACTERIZE A PRO-TUMORIGENIC CELLULAR NEIGHBORHOOD IN THE TRANSITION BETWEEN DCIS AND INVASIVE CANCER. AIM 3: CONSTRUCT AND VALIDATE A MOLECULAR PREDICTOR OF INVASIVE PROGRESSION BASED ON TWO MULTICENTER CLINICAL TRIALS OF ACTIVE SURVEILLANCE FOR DCIS. WE WILL LEVERAGE OUR TEAM’S CLINICAL, GENOMIC, SPATIAL IMAGING, AND COMPUTATIONAL EXPERTISE COMBINED WITH ACCESS TO UNIQUE CLINICAL TRIAL SAMPLES. THE DELIVERABLES FROM THIS PROJECT WILL BE TIMELY AND RELEVANT TO INFORM NEAR-TERM IMPLEMENTATION OF ACTIVE SURVEILLANCE STRATEGIES FOR LOW-RISK BREAST PRECANCERS. | $1,065,977 |